Co-Authors
This is a "connection" page, showing publications co-authored by JOHN MENDELSOHN and FUNDA MERIC-BERNSTAM.
Connection Strength
2.689
-
Correction: A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory. Oncotarget. 2019 Aug 27; 10(50):5254.
Score: 0.181
-
Expanded analysis of secondary germline findings from matched tumor/normal sequencing identifies additional clinically significant mutations. JCO Precis Oncol. 2019; 3.
Score: 0.176
-
Survival Outcomes by TP53 Mutation Status in Metastatic Breast Cancer. JCO Precis Oncol. 2018; 2018.
Score: 0.165
-
Physician interpretation of genomic test results and treatment selection. Cancer. 2018 03 01; 124(5):966-972.
Score: 0.160
-
Active Disclosure of Secondary Germline Findings to Deceased Research Participants' Personal Representatives: Process and Outcomes. JCO Precis Oncol. 2017; 1.
Score: 0.160
-
Clinical Use of Precision Oncology Decision Support. JCO Precis Oncol. 2017; 2017.
Score: 0.158
-
A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory. Oncotarget. 2017 Jun 27; 8(26):41806-41814.
Score: 0.156
-
Clinical outcomes based on multigene profiling in metastatic breast cancer patients. Oncotarget. 2016 Nov 22; 7(47):76362-76373.
Score: 0.150
-
Reply to M.P. Decatris et al. J Clin Oncol. 2016 Mar 10; 34(8):886.
Score: 0.141
-
Multigene clinical mutational profiling of breast carcinoma using next-generation sequencing. Am J Clin Pathol. 2015 Nov; 144(5):713-21.
Score: 0.139
-
Clinical next generation sequencing to identify actionable aberrations in a phase I program. Oncotarget. 2015 Aug 21; 6(24):20099-110.
Score: 0.137
-
The right drugs at the right time for the right patient: the MD Anderson precision oncology decision support platform. Drug Discov Today. 2015 Dec; 20(12):1433-8.
Score: 0.136
-
Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. J Clin Oncol. 2015 Sep 01; 33(25):2753-62.
Score: 0.135
-
A decision support framework for genomically informed investigational cancer therapy. J Natl Cancer Inst. 2015 Jul; 107(7).
Score: 0.134
-
Implementation of biomarker-driven cancer therapy: existing tools and remaining gaps. Discov Med. 2014 Feb; 17(92):101-14.
Score: 0.123
-
Building a personalized medicine infrastructure at a major cancer center. J Clin Oncol. 2013 May 20; 31(15):1849-57.
Score: 0.117
-
Precision Oncology Decision Support: Current Approaches and Strategies for the Future. Clin Cancer Res. 2018 06 15; 24(12):2719-2731.
Score: 0.041
-
"Personalized Cancer Therapy": A Publicly Available Precision Oncology Resource. Cancer Res. 2017 11 01; 77(21):e123-e126.
Score: 0.040
-
Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study. JCO Precis Oncol. 2017; 2017.
Score: 0.040
-
ALK: a tyrosine kinase target for cancer therapy. Cold Spring Harb Mol Case Stud. 2017 Jan; 3(1):a001115.
Score: 0.038
-
Prevalence of actionable mutations and copy number alterations and the price of a genomic testing panel. Oncotarget. 2016 Nov 01; 7(44):71686-71695.
Score: 0.037
-
Functional consequence of the MET-T1010I polymorphism in breast cancer. Oncotarget. 2015 Feb 20; 6(5):2604-14.
Score: 0.033
-
Clinical actionability enhanced through deep targeted sequencing of solid tumors. Clin Chem. 2015 Mar; 61(3):544-53.
Score: 0.033
-
Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma. J Invest Dermatol. 2015 Feb; 135(2):508-515.
Score: 0.032
-
The impact of tumor heterogeneity on patient treatment decisions. Clin Chem. 2013 Jan; 59(1):38-40.
Score: 0.028